The session’s discussion highlighted supply dynamics and market diversification for HPV vaccines, with UNICEF confirming five WHO-prequalified products currently available and several others in the pipeline, including a quadrivalent vaccine from SII. Participants raised questions on whether increased suppliers could reduce prices and how demand fluctuations after multi-age cohorts might affect costs. Indonesia and Lao PDR representatives emphasized concerns about sustaining budgets during Gavi transition, navigating procurement laws, and managing delays in budget disbursement. UNICEF advised that realistic planning and long-term demand forecasting remain critical for securing supply and favorable pricing. The session concluded optimistically, noting growing manufacturer interest and potential for pooled procurement to support sustainable national HPV programs.